Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31559011 | 0.91 | CASP3 (0.58) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL25294095 | 0.87 | CASP3 (0.49) | CASP3KMT2APTPN1TLR2 | |
| SCHEMBL29375426 | 0.85 | CASP3 (0.66) | CASP3KMT2ATLR2MDM4TP53 | |
| SCHEMBL26923683 | 0.85 | CASP3 (0.54) | CASP3KMT2APTPN1TLR2 | |
| SCHEMBL31217961 | 0.84 | CASP3 (0.51) | CASP3KMT2APTPN1TLR2MDM4 | |
| SCHEMBL23629963 | 0.83 | CASP3 (0.49) | CASP3KMT2ATLR2 | |
| SCHEMBL23629966 | 0.83 | CASP3 (0.49) | CASP3KMT2ATLR2 | |
| SCHEMBL23629965 | 0.83 | CASP3 (0.49) | CASP3KMT2ATLR2 | |
| SCHEMBL31217931 | 0.83 | CASP3 (0.49) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL31217786 | 0.83 | CASP3 (0.49) | CASP3KMT2APTPN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536666-A1 | ANTIBODY DRUG CONJUGATES | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| US-20250099607-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2025-03-27 | — | — | US | disclosed |
| WO-2023237050-A1 | ANTIBODY DRUG CONJUGATES | BEIGENE, LTD. (KY) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099607-A1 | ANTIBODY DRUG CONJUGATES | CD22, FCGR2A, FCGR3B | CASP3 4072/4885KMT2A 1834/4885PTPN1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.